Here are five takeaways:
1. By 2022, the market is expected to hit $1.63 billion.
2. The market was valued at $523 million last year.
3. In 2015, the hospital-acquired pneumonia and urinary tract infection segment collaboratively had a 50 percent market share.
4. North America has the largest regional presence in the market due to a high number of hospital stays and prevalence of healthcare-acquired infections.
5. Diatherix, Roche, Cantel Medical, Qiagen, Cephid and bioMeriux are key market vendors.
More articles on quality & infection control:
10% boost in hand hygiene compliance reduced HAIs by 6%: 4 takeaways
3 tips when disclosing medical errors
Valeritas names Erick Lucera new CFO — 5 points
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.